# Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer

Source: https://onco.cc/trials/nct01499303/  
OnCo record `nct01499303` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Fostamatinib in Diffuse large B-cell lymphoma, run by AstraZeneca, completed.

## Summary

Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer is a phase 2 interventional study registered as NCT01499303 by AstraZeneca, with 101 participants recorded, started 2011-12 and reaching its primary completion in 2013-10. Interventions recorded: Fostamatinib. Conditions recorded: Diffuse Large B-Cell Lymphoma.

Linked to the drug Fostamatinib because the registry names it among its interventions and Diffuse large B-cell lymphoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01499303
- Phase: 2
- Setting: Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(DLBCL)
- Sponsor: AstraZeneca
- Enrolled: 101

## Sources

- ClinicalTrials.gov NCT01499303: https://clinicaltrials.gov/study/NCT01499303

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Fostamatinib](https://onco.cc/drugs/fostamatinib/)

---
JSON: https://onco.cc/api/v1/entities/nct01499303.json